Clinical Trials Sponsored by Shandong Cancer Hospital and Institute

Total 12636 results

Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Shandong Cancer Hospital and Institute

Recruiting

Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

Limited Stage Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

Breast Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Metastatic Breast Cancer
Shandong Cancer Hospital and Institute

Not yet recruiting

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Metastatic Breast Cancer
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Metastatic Breast Cancer | HER2-positive Breast Cancer
Shandong Cancer Hospital and Institute

Unknown

Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer

Breast Cancer | Sentinel Lymph Node

China
Shandong Cancer Hospital and Institute

Unknown

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Non-Small-Cell Lung Cancer
Shandong Cancer Hospital and Institute

Unknown

Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy

Lung Neoplasms | Esophagitis | Prevention & Control | Epigallocatechin Gallate
Shandong Cancer Hospital and Institute

Unknown

Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis

Epigallocatechin Gallate | Radiation Mucositis | Radio Dermatitis
Shandong Cancer Hospital and Institute

Unknown

Temperature and Injury in Radiotherapy Radiation Skin Injury

Breast Neoplasm Female | Radiation Toxicity
Shandong Cancer Hospital and Institute

Available

Oral Green Tea Extract for Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Shandong Cancer Hospital and Institute

Unknown

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

Carcinoma, Non-Small-Cell Lung

China
Shandong Cancer Hospital and Institute

Unknown

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients (CRAGMOLC)

Carcinoma, Non-Small-Cell Lung

China
Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive (IMSLNB-CANP)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Withdrawn

Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node (Z0011-China)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative (IMSLNB-EBCP)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Completed

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Cervical Cancer | Stomach Cancer | Breast Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Ovary Cancer | Malignancies

China
Shandong Cancer Hospital and Institute

Unknown

Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients

Chronic Hepatitis B | Dysplastic Nodule of Liver
Shandong Cancer Hospital and Institute

Unknown

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival

China
Shandong Cancer Hospital and Institute

Unknown

A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma

Glioblastoma

China
Shandong Cancer Hospital and Institute

Unknown

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

Non Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Unknown

IMRT/Pemetrexed/Cisplatin in Esophageal Cancer

Esophageal Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Liver Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | HBV | PHENYTOIN/SORAFENIB [VA Drug Interaction] | DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]

China
Shandong Cancer Hospital and Institute

Recruiting

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer

Hepatocellular Carcinoma | Radiotherapy

China
Shandong Cancer Hospital and Institute

Recruiting

Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients

Neoplasms Malignant | Interstitial Pneumonia

China
Shandong Cancer Hospital and Institute

Terminated

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Completed

A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC

Esophageal Neoplasms

China
Shandong Cancer Hospital and Institute

Terminated

A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC

Esophageal Neoplasms

China
Shandong Cancer Hospital and Institute

Unknown

Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy

Breast Neoplasms | Dermatitis | Prevention & Control | Epigallocatechin Gallate
Shandong Cancer Hospital and Institute

Unknown

Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer

Metastatic Breast Cancer
Shandong Cancer Hospital and Institute

Unknown

TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular | PHENYTOIN/SORAFENIB [VA Drug Interaction]

China
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer

Colorectal Cancer | Radiotherapy | Immunotherapy | Targeted Therapy

China
Shandong Cancer Hospital and Institute

Recruiting

MRI Guided SIB Radiotherapy in Neoadjuvant Therapy for Advanced Rectal Cancer

Rectal Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort

Breast Cancer Female | Patient Reported Outcome | Breast-conserving Surgery | Oncological Safety
Shandong Cancer Hospital and Institute

Not yet recruiting

A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

HER2-positive Breast Cancer
Shandong Cancer Hospital and Institute

Recruiting

Shandong Cancer Hospital Affiliated to Shandong University

Early-stage Breast Cancer | Breast Conserving Surgery

China
Shandong Cancer Hospital and Institute

Completed

Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer

Esophageal Obstruction

China
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Cancer | HER2-positive Breast Cancer

China
Shandong Cancer Hospital and Institute

Unknown

A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

Glioblastoma
Shandong Cancer Hospital and Institute

Terminated

A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC

Esophageal Neoplasms

China
Shandong Cancer Hospital and Institute

Unknown

Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors

Advanced Cancer | Radiation Toxicity | Radiosensitivity

China
Shandong Cancer Hospital and Institute

Unknown

Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Recurrent Glioblastoma

China
Shandong Cancer Hospital and Institute

Unknown

Intraoperative Molecular Diagnosis of Sentinel Lymph Node In Breast Cancer Patients

Sentinel Lymph Node Biopsy

China

Clinical Trials Sponsored by Shandong Cancer Hospital and Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations